Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
about
In vitro and ex vivo Measurement of Prophylactic Dabigatran Concentrations with a New Ecarin-Based Thromboelastometry Test.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Global assays and the management of oral anticoagulation.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsPharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.Testing for dabigatran and rivaroxaban by clinical laboratories.Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.Incomplete dabigatran reversal with idarucizumab.A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem™ PT).[Anticoagulation-direct oral anticoagulants].Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report.Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
P2860
Q33659485-B7640F55-90A1-4EED-9799-AB7017DAAC66Q35154142-AA17845F-C7F4-4082-9A3F-D16A2C4373A1Q35164902-A9713B3D-16AE-4371-B87C-1E68D0FF2415Q35674404-BAEEAA9F-C61E-4527-8CB6-6FC5D8F1CC0AQ38386660-4884D26B-C2F6-4BEA-AD38-6762BF1AD9EAQ38458642-7899E377-C61B-4525-BEE4-9B4EFED03516Q38901666-3B27FDED-D3FB-48AE-9B7C-B738D29574AEQ38956699-7B53F6B0-9369-4430-85F1-8E87F028FFC7Q39559535-3DFC6A7D-B2BA-48D6-A95B-08BE32811FCBQ45857724-BE5731AC-78D5-4D7F-A1AC-EA5C8E3687F0Q45879084-82FEE8D0-6561-493C-9520-60244F4B2AC6Q46636532-A0B31E5B-3C72-41B1-AD6F-98997717BAC4Q48028227-751A040E-CD5E-4022-AB66-CCDE83B00E50Q52641524-92688D21-0056-420C-8606-30CB6E7DE7D2Q53063628-C54D03E5-967E-49F4-B8E9-2E7D3BE3B727Q53606345-93E10367-7A93-4E43-8ED4-4C3D05207477Q59129911-381ACB4C-CA94-41DE-94C4-E33554ED0499
P2860
Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Influence of dabigatran and ri ...... . A nationwide Belgian survey.
@en
Influence of dabigatran and ri ...... . A nationwide Belgian survey.
@nl
type
label
Influence of dabigatran and ri ...... . A nationwide Belgian survey.
@en
Influence of dabigatran and ri ...... . A nationwide Belgian survey.
@nl
prefLabel
Influence of dabigatran and ri ...... . A nationwide Belgian survey.
@en
Influence of dabigatran and ri ...... . A nationwide Belgian survey.
@nl
P2093
P50
P356
P1476
Influence of dabigatran and ri ...... s. A nationwide Belgian survey
@en
P2093
Anne Demulder
Bernard Chatelain
Els Bailleul
Katrien Devreese
Kris Vernelen
Kristin Jochmans
Marjan Van Blerk
Mohamed Rida Soumali
Philippe Van de Walle
Walter Wijns
P304
P356
10.1160/TH14-02-0161
P577
2014-09-18T00:00:00Z